10058-F4 is a specific small-molecule c-Myc inhibitor. It affects MYC and NF-κB signaling pathways by blocking c-Myc-Max heterodimerization and target gene transcription, effectively inhibiting cancer cell proliferation, metabolic reprogramming, and promoting apoptosis.